BR0211492A - Vacina para west nile - Google Patents

Vacina para west nile

Info

Publication number
BR0211492A
BR0211492A BR0211492-5A BR0211492A BR0211492A BR 0211492 A BR0211492 A BR 0211492A BR 0211492 A BR0211492 A BR 0211492A BR 0211492 A BR0211492 A BR 0211492A
Authority
BR
Brazil
Prior art keywords
west nile
vaccine
provides
disease
vaccine composition
Prior art date
Application number
BR0211492-5A
Other languages
English (en)
Other versions
BRPI0211492B1 (pt
Inventor
Hsien-Jue Chu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0211492A publication Critical patent/BR0211492A/pt
Publication of BRPI0211492B1 publication Critical patent/BRPI0211492B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"VACINA PARA WEST NILE". A presente invenção fornece uma composição de vacina segura e eficaz contra doença de vírus West Nile. Um componente imunogenicamente ativo de vírus West Nile ou DNA de plasmídeo, um adjuvante tal como um óleo metabolizável, e um veículo farmacologicamente aceitável são formulados em uma vacina imunizante. A invenção também fornece um método para a prevenção ou melhora de doença de West Nile, tais como encefalite, em eq³ídeo administrando a composição de vacina descrita aqui.
BRPI0211492A 2001-07-27 2002-07-23 "composição de vacina para uso na prevenção ou melhora de encefalite de west nile em equídeos, e uso de um componente imunogenicamente ativo na preparação da mesma BRPI0211492B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
BR0211492A true BR0211492A (pt) 2004-08-17
BRPI0211492B1 BRPI0211492B1 (pt) 2016-06-21

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0211492A BRPI0211492B1 (pt) 2001-07-27 2002-07-23 "composição de vacina para uso na prevenção ou melhora de encefalite de west nile em equídeos, e uso de um componente imunogenicamente ativo na preparação da mesma

Country Status (25)

Country Link
US (8) US7153513B2 (pt)
EP (3) EP1427444B1 (pt)
JP (2) JP4718778B2 (pt)
KR (2) KR20040028952A (pt)
CN (2) CN1273189C (pt)
AU (1) AU2002365244B2 (pt)
BE (1) BE2014C006I2 (pt)
BR (1) BRPI0211492B1 (pt)
CA (1) CA2452545C (pt)
CY (1) CY2014010I1 (pt)
DK (1) DK1427444T3 (pt)
ES (1) ES2435095T3 (pt)
FR (1) FR14C0016I2 (pt)
HK (1) HK1066470A1 (pt)
HR (1) HRP20040195B1 (pt)
HU (2) HU228690B1 (pt)
LU (1) LU92348I2 (pt)
ME (1) ME00491B (pt)
MX (1) MXPA04000680A (pt)
NZ (3) NZ531265A (pt)
PL (2) PL212212B1 (pt)
PT (1) PT1427444E (pt)
RS (1) RS53184B (pt)
WO (1) WO2003061555A2 (pt)
ZA (1) ZA200401596B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
DK1427444T3 (da) * 2001-07-27 2013-11-04 Zoetis W Llc West-nil-vaccine
WO2005024427A2 (en) * 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
JP2008534598A (ja) * 2005-04-01 2008-08-28 ワイス 免疫原の干渉を克服するための、慣習的なワクチンと組み合わせたｄｎａワクチンの使用
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
JP5193856B2 (ja) * 2005-06-24 2013-05-08 インターベツト・インターナシヨナル・ベー・ベー 不活化キメラワクチン及び関連する使用方法
RU2520081C2 (ru) * 2005-10-19 2014-06-20 Юниверсити Оф Флорида Рисерч Фаундейшн, Инк Вирус гриппа, способный инфицировать собачьих, и его применение
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
DK2395018T3 (en) * 2006-06-06 2016-04-25 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
US9056909B2 (en) * 2007-11-06 2015-06-16 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2306812A4 (en) * 2008-07-30 2013-02-20 Univ Kentucky Res Found EQUINE DISEASE MODEL FOR NEUROLOGICAL AUROPTIC VIRUS DISEASE AND USED ASSAYS
EP2334327B1 (en) * 2008-08-29 2016-01-06 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
AU2010303741A1 (en) * 2009-10-07 2012-04-19 Zoetis W Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
MX350718B (es) 2011-03-14 2017-09-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
WO2014186291A1 (en) * 2013-05-14 2014-11-20 Zoetis Llc Novel vaccine compositions comprising immunostimulatory oligonucleotides
WO2015034903A1 (en) * 2013-09-05 2015-03-12 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
EP3930749A1 (en) 2019-02-27 2022-01-05 University of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
SI0968722T1 (sl) * 1994-05-10 2007-10-31 Wyeth Corp Izboljĺ ano, modificirano ĺ˝ivo cepivo proti brsv
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7417136B1 (en) 1998-06-04 2008-08-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP2004510714A (ja) * 2000-10-04 2004-04-08 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア フラビウイルス及びペスチウイルス由来のキャプシド蛋白質を使用する組成物及び方法
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
AU2002309508A1 (en) * 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
DK1427444T3 (da) * 2001-07-27 2013-11-04 Zoetis W Llc West-nil-vaccine
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
US20070166324A1 (en) 2007-07-19
KR20090053967A (ko) 2009-05-28
NZ531265A (en) 2008-08-29
AU2002365244B2 (en) 2007-12-06
RS53184B (en) 2014-06-30
US20070166325A1 (en) 2007-07-19
HK1066470A1 (en) 2005-03-24
PL220846B1 (pl) 2016-01-29
EP2281572A1 (en) 2011-02-09
PT1427444E (pt) 2013-11-19
US20070166326A1 (en) 2007-07-19
NZ553165A (en) 2008-09-26
BRPI0211492B1 (pt) 2016-06-21
HUS1300055I1 (hu) 2016-08-29
HU228690B1 (en) 2013-05-28
EP1427444A4 (en) 2008-01-02
CN1273189C (zh) 2006-09-06
HRP20040195B1 (hr) 2014-07-18
ZA200401596B (en) 2005-07-27
JP4718778B2 (ja) 2011-07-06
JP2005515236A (ja) 2005-05-26
US7648706B2 (en) 2010-01-19
YU8004A (sh) 2006-08-17
MXPA04000680A (es) 2004-04-05
CN1535157A (zh) 2004-10-06
HRP20040195A2 (en) 2004-08-31
CN1935258B (zh) 2013-04-03
EP2283858A2 (en) 2011-02-16
CN1935258A (zh) 2007-03-28
LU92348I9 (pt) 2019-01-02
US7648705B2 (en) 2010-01-19
ME00491B (me) 2011-10-10
US7153513B2 (en) 2006-12-26
ES2435095T3 (es) 2013-12-18
US20030091595A1 (en) 2003-05-15
CA2452545C (en) 2015-06-09
LU92348I2 (fr) 2014-09-22
US20070178119A1 (en) 2007-08-02
FR14C0016I1 (pt) 2014-03-28
WO2003061555A3 (en) 2004-04-15
HUP0401606A2 (hu) 2004-11-29
PL368535A1 (en) 2005-04-04
EP2283858A3 (en) 2011-03-23
CY2014010I1 (el) 2020-05-29
WO2003061555A2 (en) 2003-07-31
BE2014C006I2 (pt) 2021-02-04
PL398575A1 (pl) 2012-06-18
US7445787B2 (en) 2008-11-04
FR14C0016I2 (fr) 2015-07-24
HUP0401606A3 (en) 2005-02-28
CA2452545A1 (en) 2003-07-31
PL212212B1 (pl) 2012-08-31
NZ570270A (en) 2010-08-27
US20070231349A1 (en) 2007-10-04
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
US20070231350A1 (en) 2007-10-04
KR20040028952A (ko) 2004-04-03
DK1427444T3 (da) 2013-11-04
US20070166802A1 (en) 2007-07-19
JP2011057692A (ja) 2011-03-24

Similar Documents

Publication Publication Date Title
BR0211492A (pt) Vacina para west nile
GB0025577D0 (en) Vaccine
NO20070551L (no) Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
YU92102A (sh) Metode i smeše za lečenje virusnog hepatitisa c
BR0200155A (pt) Tratamento combinado para depressão
BR0013154A (pt) Vacina recombinante para o envelope contra infecção de flavivìrus
IL168584A (en) West nile virus vaccine
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
MY153290A (en) Multivalent avian influenza vaccines
CY1108482T1 (el) Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
YU44102A (sh) Ciklična kvaternerna amonijum jedinjenja
BR0312640A (pt) Formulação contra mycoplasma gallisepticum
DE602004009664D1 (de) Diclazurilhaltige antiprotozoenmittel
YU65102A (sh) In ovo zaštita protiv infektivnog bronhitisa
BRPI0408249A (pt) vacinas bovinas com adjuvante
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
CY1114624T1 (el) Εμβολιο δυτικου νειλου
EP1582220A4 (en) COMPOSITION FOR TOPICAL ANESTHESIA
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease
BR0014447A (pt) Derivados de piperidina como inibidores da reabsorção
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B25A Requested transfer of rights approved

Owner name: PAH W LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.

B25D Requested change of name of applicant approved

Owner name: ZOETIS W LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25G Requested change of headquarter approved